To assess risk for importation of dengue virus (DENV) into Queensland, Australia, and sources of imported viruses, we sequenced the envelope region of DENV isolates from symptomatic patients with a history of travel during 2002–2010. The number of imported dengue cases greatly increased over the surveillance period, some of which were associated with domestic outbreaks. Patients reported traveling to (in order) Asia, Papua New Guinea, Pacific Island countries, and non–Asia-Pacific countries. By using phylogenetic methods, we assigned DENV isolates from returning residents and overseas visitors with viremia to a specific genotypic group. Genotypes circulating in Asia were extremely diverse. Genotyping and molecular clock analysis supported Asian origination of a strain that caused an outbreak of DENV-4 in Pacific Island countries during 2007–2009, and subsequently, in Innisfail, Australia, in 2009. Our findings indicate that Asia is a major source of DENVs that are imported into Australia, causing a risk for epidemics.

Queensland, a state located in the tropical and subtropical northeastern area of Australia, has a long history of dengue virus (DENV) activity. Dengue was present in the late 19th century (1) and, following a lull for most of the 20th century, dengue importation and epidemic transmission have been increasingly reported in the past 20 years (2,3). Epidemics of the disease have occurred historically in other states of Australia, but only in Queensland have epidemics been reported in recent times. These epidemics were caused by the distribution of the vector, *Aedes aegypti* mosquitoes. The species was once found in other Australian states, but its area of distribution has now contracted so that it lies almost exclusively within Queensland’s borders (4,5).

Despite repeated transmission events, dengue is not endemic to Queensland, and transmission requires a viremic traveler to import the virus to initiate epidemic spread (6). Rapid identification of cases and disease tracking, incorporating targeted vector surveillance, and control measures adopted rigorously to limit epidemic potential have been major factors in preventing local transmission and in reducing the cost of managing mosquito-borne disease (7).

With the apparent increasing frequency of dengue epidemics and imported cases, the disease has become a major public health issue. Exposure to multiple serotypes of DENV, of which there are 4 in total, may result in a higher probability of potentially life-threatening conditions such as dengue hemorrhagic fever and dengue shock syndrome, a potentially life-threatening condition (8). Perhaps not coincidentally, 2 fatal cases of dengue hemorrhagic fever were reported in 2004 in Queensland, and the serologic profile of the case-patients indicated secondary infection consistent with dengue shock syndrome (9). Of additional concern is the possibility that the virus may become endemic if case numbers were to rise to a point at which vector control measures became ineffectual at controlling virus spread.

Recent DENV infection is diagnosed by serologic testing, through virus isolation or by nucleic acid amplification by reverse transcription PCR (RT-PCR). The advantage of the latter is that sequencing of reaction products enables a definitive diagnosis of acute infection, identification of the virus serotype, and genotyping. As an adjunct to isolation techniques, sequencing and genotyping can provide valuable evidence of importation or can confirm local transmission and enable differentiation between multiple circulating strains and serotypes.
Analysis of DENV sequence data facilitates rapid disease tracking and vector control. However, not all specimens are suitable for RT-PCR because infected persons usually exhibit a relatively short-lived viremia early in the febrile period (10). In addition, clinicians may find it difficult to obtain acute-phase samples, particularly if patients delay their initial consultation or are still in transit during their viremic phase.

As part of control measures by Queensland Public Health, we sequenced the envelope region of DENV isolates from symptomatic patients with a history of travel during 2002–2010. The proportion of the 4 DENV serotypes that were imported was determined, as well as the geographic origin of each serotype. Phylogenetic trees containing imported DENV viruses and others strains circulating throughout the world (from GenBank) were constructed by using a maximum likelihood model. From this analysis, we ascertained the likely geographic origin of imported viruses. This enabled us to assess the risk for importation of DENV from various sources by travelers entering Australia.

Materials and Methods

Virus Samples

Serum samples from patients with suspected DENV infection were referred to the Public Health Virology Laboratory, Queensland Health Forensic and Scientific Services, following the directive of Queensland Public Health medical officers, or were obtained through the public or private laboratory network. Acute-phase specimens underwent RT-PCR and serologic testing, and those that successfully yielded an RT-PCR product (after specific DENV serotype amplification) were sequenced and genotyped by phylogenetic analyses to assist public health investigations. This work was approved by the Ethics Committee of Queensland Health Forensic and Scientific Services.

Viral RNA Extraction and Nucleotide Sequencing

RNA was extracted from 200 μL of serum, either manually (QIAamp viral RNA extraction kit; QIAGEN, Hilden, Germany) or by using the EZ1 Virus Mini Kit and (QIAGEN) according to the manufacturer’s instructions. Amplification was performed for each DENV serotype by using the Superscript III/Platinum Taq High Fidelity One-Step RT-PCR System (Invitrogen, Carlsbad, CA, USA) with specific RT-PCR primers (Table 1, Appendix, wwwnc.cdc.gov/EID/article/18/11/12-0014-T1.htm). Nucleotide sequencing of the complete envelope gene region (DENV-1, DENV-2, and DENV-4: 1,485 bp; DENV-3: 1,479 bp) was performed by using the Big Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequence data obtained were deposited in GenBank (Table 2, Appendix, wwwnc.cdc.gov/EID/article/18/11/12-0014-T2.htm).

Phylogenetic Analysis of Envelope Protein Sequence

Full-envelope protein sequences for each serotype were aligned by using the multiple alignment tool of MEGA5 (www.megasoftware.net). Unrooted trees were then constructed by using a maximum likelihood estimation with a Jukes-Cantor model and γ-distributed rates, and by constructing 1,000 replicates to generate bootstrap support values. Divergence time from a common ancestor was estimated by using the molecular clock calculator.

Results

Increasing Incidence of Dengue Outbreaks and Serotype Diversity

Previous reports (3,11) and anecdotal evidence indicated that there has been an increase in the number of dengue outbreaks occurring in Queensland. To investigate this apparent trend, we combined recent and historical outbreak data (3) over a 20-year period. A 5-year moving average does indeed show trends of increasing dengue outbreak incidence and increasing diversity of DENV serotypes that cause such outbreaks (Figure 1, panels A, B). A line of best fit revealed a significant increase with time ($r^2 = 0.48$; $p < 0.05$ by Student $t$ test, 2-tailed). All 4 DENV serotypes caused outbreaks; DENV-2 was the most common cause (50.0%), followed by DENV1 and DENV-3 (19.4% each) and DENV-4 (11.1%) (Figure 1, panel C). The increase in outbreak incidence reflects changes in international travel over this period, which has increased 3.5-fold since the early 1990s (12). This increase is consistent with increased importations of virus carried by viremic travelers and the recognized increase in DENV infections throughout the world (13). Also of note is the dramatic increase in infections caused by imported viruses in 2010 (Figure 1, panel D).

Geographic Origins and Diversity of Imported DENVs, 2002–2010

We ascertained the number and diversity of imported DENV serotypes from infected travelers during 2002–2010 (Table 3). This period was chosen because the most comprehensive patient sequence data were available. Information was analyzed from viremic travelers, for whom an RT-PCR amplification product and serotype designation could be obtained. The possible strain origins, which were determined after phylogenetic analyses, were compared with available travel histories to ascertain likely geographic origins of the infecting virus. The data were categorized into 4 separate regions: Asia, Papua New
Guinea (PNG), the Pacific Islands, and countries outside of the Asia-Pacific region (non–Asia-Pacific).

Most infected travelers (77.9%) reported spending time abroad in Asia. In particular, 26.4% of all virus importations could be traced to Indonesia alone. All 4 DENV serotypes were detected in the specimens sequenced from persons with a travel history to that country. Notably, patients reported traveling to other Asian countries, including Thailand and the Philippines, where all 4 DENV serotypes have been found. Most other countries to which travel was reported had at least 3 DENV serotypes (Timor-Leste, PNG, and Vietnam), 2 serotypes (Cambodia, India, Fiji, Malaysia, and Laos), or 1 serotype (Brazil, Guyana, Samoa, Singapore, Solomon Islands, Sri Lanka, Tonga, and Vanuatu). A greater degree of diversity cannot be excluded in many of these countries because sampling numbers for individual countries were often low.

We calculated the proportion of the 4 DENV serotypes for infected travelers (Figure 2, panel A), which was slightly different from the proportion associated with outbreaks within Queensland (Figure 1, panel C). The serotype most commonly imported by travelers was DENV-1 (39.3%), followed by DENV-2 (25.7%), DENV-3 (21.4%), and DENV-4 (13.6%). Strains of all 4 DENV serotypes originated mainly in Asia (Figure 2, panel B). DENV-1 had the most diverse origins, with patients reporting travel mainly to Asia, but also to PNG, the Pacific Islands, and non–Asia-Pacific regions. In addition to Asia, DENV-2 was found to originate in PNG; DENV-3 originated in PNG and a non–Asia-Pacific area (Brazil); and DENV-4 originated in the Pacific Islands.

Origins of DENVs Imported by Returning Residents

Infected travelers were either returning Queensland residents or international visitors. Returning residents were the largest proportion of patients (96.4%) who sought treatment from the health system with dengue viremia. Further analysis was conducted on the subset of returning residents (135 of 140 patients with imported cases). Similarly to the analysis of all travelers above, infected
Imported Dengue Viruses, Australia

returning residents (Table 4) reported that they had most frequently returned from Asia (77.0%), followed by PNG (13.3%), then the Pacific Islands (8.1%), and least often from non–Asia-Pacific areas (1.5%). The overall ratio was significantly different from that expected on the bases of the proportion of all Queensland residents who reported returning from dengue-endemic countries of those 4 regions, as calculated by using data from the Australian Bureau of Statistics for 2002–2010 ($\chi^2$ analysis, $p = 0.0004$). The proportion of patients reporting travel to Asia, and to PNG in particular, was higher than expected. The overrepresentation of cases from PNG is best explained by

| Region and country | No. (%) cases | Dengue serotypes (genotypes) |
|--------------------|---------------|-----------------------------|
| Asia               |               |                             |
| Indonesia          | 37 (26.4)     | 1 (I, IV), 2 (Cosmopolitan), 3 (I), 4 (II) |
| Thailand           | 15 (10.7)     | 1 (I), 2 (Asian genotype I), 3 (II), 4 (I) |
| Philippines        | 10 (7.1)      | 1 (IV), 2 (Cosmopolitan), 3 (I), 4 (I) |
| India              | 9 (6.4)       | 1 (V), 2 (Cosmopolitan) |
| Timor-Leste        | 9 (6.4)       | 1 (IV), 2 (Cosmopolitan), 4 (II) |
| Vietnam            | 7 (5.0)       | 1 (I), 2 (Asian genotype I), 3 (II) |
| Malaysia           | 5 (3.6)       | 1 (I, IV), 4 (II) |
| Laos               | 2 (1.4)       | 1 (I), 2 (Asian genotype I) |
| Cambodia           | 2 (1.4)       | 1 (I), 3 (II) |
| Singapore          | 1 (0.7)       | 1 (I) |
| Sri Lanka          | 1 (0.7)       | 1 (V) |
| Asia, not specified| 11 (7.9)      | – |
| Papua New Guinea   | 19 (13.6)     | 1 (I, IV), 2 (Cosmopolitan), 3 (I) |
| Pacific Islands    |               |                             |
| Fiji               | 4 (2.9)       | 1 (IV), 4 (II) |
| Samoa              | 2 (1.4)       | 4 (II) |
| Solomon Islands    | 1 (0.7)       | 1 (ND) |
| Tonga              | 3 (2.1)       | 4 (ND) |
| Vanuatu            | 1 (0.7)       | 4 (ND) |
| Non–Asia-Pacific   |               |                             |
| Brazil             | 1 (0.7)       | 3 (ND) |
| Guyana             | 1 (0.7)       | 1 (V) |
| Total              | 140           |                             |

*ND, not determined

Figure 2. Importation of dengue viruses (DENVs) into Queensland, Australia, 2002–2010. A) Proportion of imported DENV serotypes. B) Geographic origins of the 4 imported DENV serotypes. D1–D4, DENV-1–DENV-4; PNG, Papua New Guinea.
a recent increase in DENV activity in that country, which is consistent with a large number of importations from PNG (47.4%) during 2010 (Figure 1, panel D) and, in addition, other recent reports (14). In comparison, the proportion of patients who reported travel to the Pacific Islands was lower than expected. Because only 2 cases originated in the non–Asia-Pacific region, it was subsequently difficult to draw conclusions about this region for statistical purposes.

**Genotype Assignment of Imported DENVs**

The genotypic mix for the various regions from which dengue was imported is shown in Table 3 and Figures 3–6. Across all regions, viruses could be classified into 1 of 2 genotypic groups within each serotype; the exception was DENV-1, which had 3 groups. In countries which were a source of imported viruses, generally 1 genotypic group for each serotype predominated.

DENV genotypic groups generally circulate in particular regions (15). The viruses imported into Queensland were consistent with DENV genotypes which had previously been reported to circulate in those countries to which patients had reported travel (16–19). For example, DENV-4 genotypic group II has been reported in Indonesia, Tahiti, the Caribbean Islands, and Central and South America (17). In 2007–9, DENV-4 was introduced into the Pacific Islands, displacing DENV-1 in the process (20,21). Our genotypic analysis confirms classification of the Pacific Island DENV-4 in genotypic group II, as recently reported (21). This was the first time this genotypic group had been reported in the Pacific region, and suggested that the origin of this strain of DENV-4 may have been Southeast Asia.

In support of this suggestion, a closely related DENV-4 strain from the Torres Strait (Figure 6, JN575595) with 99.1% envelope nucleotide identity to a DENV-4 strain from Samoa (Figure 6, JN575592), was detected before the Pacific outbreak in 2005. A maximum likelihood test of the phylogenetic tree determined that a molecular clock was applicable (H_0 not rejected; p = 0.06). Using a previously published substitution rate for dengue 4 of 1 × 10^{-3} substitutions/site/year (22), we calculated that divergence from a common ancestor occurred in ≈2002 with an error of ± 2 years. Thus, the Pacific Island outbreak strain (Figure 6, Pacific Island clade) is geographically and temporally closely related to the Torres Strait 2005 virus. Both of these virus strains are mostly closely related to DENV-4 strains which originated in Indonesia (Figure 6, JN575583). These data support suggestions the Pacific Island outbreak strain originated in Indonesia and made its way to the Torres

---

**Table 4. Observed and expected numbers of imported DENVs by region, Queensland, Australia, 2002–2010**

| Imported DENVs | No. (%) from Asia† | No. (%) from Papua New Guinea | No. (%) from Pacific Islands | No. (%) from non–Asia-Pacific region |
|----------------|---------------------|-----------------------------|-----------------------------|-----------------------------------|
| Observed       | 104 (77.0)          | 18 (13.3)                   | 11 (8.1)                    | 2 (1.5)                            |
| Expected       | 92 (68.2)           | 18 (13.9)                   | 28 (20.8)                   | 4 (3.2)                            |

*χ² is 18 (p<0.0004; 2-tailed test); DENVs, dengue viruses.
†Asia includes travelers to Indonesia, Timor-Leste, Thailand, India, Malaysia, Philippines, Vietnam, Singapore, Cambodia, Sri Lanka and Laos; Papua New Guinea; Pacific Islands includes travelers to Fiji, Samoa, Solomon Islands, Tonga, and Vanuatu; non–Asia-Pacific region was defined as all cases outside the Asia-Pacific region which included Brazil and Guyana.
‡Based on travel data from the Australian Bureau of Statistics (www.abs.gov.au/) for departing Queensland residents who named the country where they planned to spend the most time, selected for those countries designated as having an ongoing dengue transmission risk, according to the Centers for Disease Control and Prevention Dengue Map (www.healthmap.org/dengue).
Imported Dengue Viruses, Australia

... Strait (Australia) in 2005, probably through PNG, and into the Pacific in 2007 where it is currently circulating. A virus most closely related to the Pacific Island strain was then imported into Innisfail in northern Queensland in 2009, where it caused an outbreak (Figure 6). This incident highlights the epidemic potential of DENV strains that are imported into Queensland (3,23,24).

Discussion

In this study we have analyzed the importation of DENVs into northern Queensland, the only area within Australia where domestic epidemic spread is a risk. Two issues are apparent from these analyses. First, DENV infections, in terms of the number of importations and outbreaks, have increased in recent years. This issue is most apparent when it is considered that 42.9% of all instances of virus importation identified in this study occurred in 2010. The greatest risk was from residents returning from travel overseas, rather than overseas visitors. However, cases in the latter may be somewhat underreported because they may be more reluctant to seek medical assistance in a foreign country.

The second issue is the large degree of risk that Asia represents as a primary source of DENVs that can cause epidemics in Australia. Not only does Asia represent the biggest source of imported viruses in terms of number and serotype diversity, but it is also a source of viruses that can be imported into the Pacific region and, subsequently, a secondary source of importation into Australia as can be seen from the outbreak of the Pacific Island DENV-4 genotypic group II in Innisfail in 2009. If suggestions that the Pacific Island states are unable to sustain long-term DENV circulation are correct (20), then Asia may also be an important source of new outbreaks in the Pacific by...
incursions perhaps from either PNG or the islands of the Torres Strait.

To determine whether travelers returning from the 4 regions were either underrepresented or overrepresented in the dataset, we compared travelers departing Australia (using information obtained from outgoing passenger cards). A subset of Queensland residents was used as this information was available from the Australian Bureau of Statistics only for outgoing residents. The overrepresentation of infections imported from Asia and PNG relative to the Pacific Island countries may be due to higher levels of DENV activity in those countries. In the case of PNG, this result was mostly due to a large increase in imported DENVs from that country in 2010 (47.4% of all imported DENVs from PNG). Data from 2011 continue this trend to higher levels of DENVs imported from that country (data not shown). A previous study noted a decline in imported DENVs from PNG from 51% over the period 1999–2003 to 12% from 2004 to 2008 (25). The findings from this study may indicate a return to the historically higher proportion of imported DENVs from that region with the likelihood that recent dengue activity in PNG has intensified.

Little is known about overt disease in adults who acquire DENV-2 and DENV-4 infections. Disease may only be seen in those persons with previous antibody responses to another dengue serotype (26). This circumstance has implications for vaccine development because those persons with DENV antibodies may experience disease when exposed to vaccine formulations that contain apparently attenuated DENV-2 and DENV-4 (26). Susceptible adults who contract dengue while traveling represent an opportunity to study the factors associated with overt disease. To explore the pathogenicity of DENV-2 and DENV-4, serologic responses should be correlated, in the context of patient age, with molecular diagnostics in future studies of dengue surveillance.

This work clearly shows the increasing risk that viremic travelers pose to Australia, and to Queensland in particular, as a means for importing DENVs that could have substantial outbreak potential. Molecular epidemiologic studies have identified Asia as the greatest source of DENV infections that have been imported into Queensland recently. The increase in imported DENV strains and the number of outbreaks is of major public health importance and has been largely exacerbated by the heightened frequency and affordability of modern air travel. As this trend continues, the chance of the virus becoming endemic and the likelihood of the recurrence of disease also increase. Although additional studies are required to investigate the clinical implications of the imported viruses and specific patient anomalies, the sequence information presented here could assist future understanding of viral markers in relation to symptomatic disease and their association with pathogenesis.

Acknowledgments

We are grateful for the substantial contribution made by Queensland Public Health medical officers and thank private and public health practitioners for coordinating specimen collection and providing relevant clinical data and patient travel histories. We also thank the staff of Queensland Health Forensic and Scientific Services who assisted in the processing of specimens and routine diagnostics.

Dr Warrillow is currently the research and development coordinator at Public Health Virology, Queensland Health Forensic and Scientific Services. He has investigated viruses of human health importance, including arboviruses, Australian bat lyssavirus, and HIV, and his current research interests focus on RNA virus replication, diagnostics, and virus discovery.

References

1. McBride JH. Dengue fever. An Australian perspective. Aust Fam Physician. 1999;28:319–23.
2. Hanna JN, Richards AR, Esmonde JV, Donohue S, Humphreys JL, Pyke AT, et al. Virameric importations of dengue into north Queensland, 2009. Commun Dis Intell. 2010;34:57–8.

3. Hanna JN, Ritchie SA. Outbreaks of dengue in north Queensland, 1990–2008. Commun Dis Intell. 2009;33:32–3.

4. Beebe NW, Cooper RD, Mottram P, Sweeney AW. Australia’s dengue risk driven by human adaptation to climate change. PLoS Negl Trop Dis. 2009;3:e429. http://dx.doi.org/10.1371/journal.pntd.0000429

5. Russell RC, Currie BJ, Lindsay MD, Mackenzie JS, Ritchie SA, Whelan PL. Dengue and climate change in Australia: predictions for the future should incorporate knowledge from the past. Med J Aust. 2009;190:265–8.

6. McBride WJ. Dengue fever: is it endemic in Australia? Intern Med J. 2010;40:247–9. http://dx.doi.org/10.1111/j.1445-2009.2009;190:265–8.

7. Vazquez-Prokopec GM, Chaves LF, Ritchie SA, Davis J, Kitron U. Unforeseen costs of cutting mosquito surveillance budgets. PLoS Negl Trop Dis. 2010;4:e588. http://dx.doi.org/10.1371/journal.pntd.0000585

8. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11:480–96.

9. McBride WJ. Dengue hemorrhagic fever: the first in Australia in over a century. Med J Aust. 2005;183:35–7.

10. Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A. Viraemia in patients with naturally acquired dengue infection. Bull World Health Organ. 1981;59:623–30.

11. Fitzsimmons GJ, Wright P, Johansen CA, Whelan PL. Arboviral diseases and malaria in Australia, 2008–09: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell. 2010;34:225–40.

12. Australian Bureau of Statistics. 3401.0–Overseas arrivals and departures, Australia, Jan 2012 [cited 2012 February]. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3401.0Jan%202012/OpenDocument

13. Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008;62:71–92. http://dx.doi.org/10.1146/annurev.micro.62.081307.163005

14. Senn N, Luang-Saarkia D, Manong D, Siba PM, McBride WJ. Contribution of dengue fever to the burden of acute febrile illnesses in Papua New Guinea: an age-specific prospective study. Am J Trop Med Hyg. 2011;85:132–7. http://dx.doi.org/10.4269/ajtmh.2011.10-0482

15. Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res. 2010;85:328–45. http://dx.doi.org/10.1016/j.antiviral.2009.10.008

16. Goncalvez AP, Escalante AA, Pujol FH, Ludert JE, Tovar D, Salas RA, et al. Diversity and evolution of the envelope gene of dengue virus type 1. Virology. 2002;303:110–9. http://dx.doi.org/10.1006/viro.2002.1686

17. Lanciotti RS, Gubler DJ, Trent DW. Molecular evolution and phylogeny of dengue-4 viruses. J Gen Virol. 1997;78:2279–84.

18. Twiddy SS, Farrar JJ, Vinh Chau N, Wills B, Gould EA, Gritsun T, et al. Phylogenetic relationships and differential selection pressures among genotypes of dengue-2 virus. Virology. 2002;298:63–72. http://dx.doi.org/10.1006/viro.2002.1447

19. Wittke V, Robb TE, Thu HM, Nisalak A, Nimmannitya S, Kalayanarooj S, et al. Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period. Virology. 2002;301:148–56. http://dx.doi.org/10.1006/viro.2002.1549

20. Li DS, Liu W, Guigon A, Mostyn C, Grant R, Aaskov J. Rapid displacement of dengue virus type 1 by type 4, Pacific region, 2007–2009. Emerg Infect Dis. 2010;16:123–5. http://dx.doi.org/10.3201/eid1601.091275

21. Cao-Lormeau VM, Roche C, Aubry M, Teissier A, Lastere S, Daudens E, et al. Recent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands. PLoS ONE. 2011;6:e29555. http://dx.doi.org/10.1371/journal.pone.0029555

22. Vasilakis N, Holmes EC, Fokam EB, Faye O, Diallo M, Sall AA, et al. Evolutionary processes among syphlic dengue type 2 viruses. J Virol. 2007;81:9591–5. http://dx.doi.org/10.1128/JVI.02776-06

23. Hanna JN, Ritchie SA, Hills SL, Pyke AT, Montgomery BL, Richards AR, et al. Dengue in north Queensland, 2002. Commun Dis Intell. 2003;27:384–9.

24. Hanna JN, Ritchie SA, Richards AR, Humphreys JL, Montgomery BL, Ehlers GJ, et al. Dengue in north Queensland, 2005–2008. Commun Dis Intell. 2009;33:198–203.

25. Hanna JN, Ritchie SA. An apparent recent decline in importations of dengue from Papua New Guinea into north Queensland. Commun Dis Intell. 2009;33:34–5.

26. Vaughn DW. Invited commentary: dengue lessons from Cuba. Am J Epidemiol. 2000;152:800–3. http://dx.doi.org/10.1093/aje/152.9.800

Address for correspondence: David Warrilow, Public Health Virology Laboratory, Queensland Health Forensic and Scientific Services, PO Box 594, Archerfield, Queensland 4108, Australia; email: David_Warrilow@health.qld.gov.au

The Public Health Image Library (PHIL)

The Public Health Image Library (PHIL), Centers for Disease Control and Prevention, contains thousands of public health-related images, including high-resolution (print quality) photographs, illustrations, and videos.

PHIL collections illustrate current events and articles, supply visual content for health promotion brochures, document the effects of disease, and enhance instructional media.

PHIL Images, accessible to PC and Macintosh users, are in the public domain and available without charge.

Visit PHIL at http://phil.cdc.gov/phil.